-

IAMA Therapeutics to Present at Upcoming BIO International Convention

GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, today announced that Andrea Malizia, Chief Executive Officer, will present at the BIO International Convention, taking place June 5-8, 2023, in Boston, MA.

BIO International Convention
Format: Company Presentation
Date: Wednesday, June 7, 2023
Time: 10:45 AM ET

About IAMA Therapeutics

IAMA Therapeutics is a Series A late-preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in children suffering from epilepsy and neurodevelopmental disorders. IAMA Therapeutics couples emerging advances in drug discovery and neurobiology to selectively inhibit the cation chloride cotransporters and other therapeutic targets relevant to brain disorders characterized by neuronal imbalance.

For more information, please visit https://iamatherapeutics.com/.

Contacts

Andrea P. Malizia
media@iamatherapeutics.com

Sarah Sutton/Georgia West
Argot Partners
iama@argotpartners.com

More News From IAMA Therapeutics

IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that the first subject was treated with IAMA-6, an orally administered small molecule therapeutic targeting NKCC1. IAMA-6, IAMA’s lead program, is being evaluated for the treatment of autism and epilepsy in a Phase 1 first-in-human (FIH), randomized, double-blind, placebo-controlled, s...

IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that the Italian Medicines Agency (AIFA) has accepted the Clinical Trial Application (CTA) to initiate a Phase 1 first-in-human (FIH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerabili...

IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting

GENOA, Italy--(BUSINESS WIRE)--IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that it will present a poster titled “Selective NKCC1 Inhibitors for the Treatment of Refractory Epilepsy” at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1-5 in Orlando, FL. “The altered expression of chloride importer NKCC1, which can lead to an imba...
Back to Newsroom